Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...

Abbott India said that it has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals Company to commercialize Vonoprazan, a novel molecule in the gastrointestinal therapy area, ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...

Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

Abbott's strong innovation pipeline, including advancements in CGM systems, supports its market share gains and growth ...

Abbott's inquest into radiopharmaceuticals In 1946, Abbott became the first pharmaceutical company to have a special laboratory for radiopharmaceuticals – a move that led to the creation of the ...

The Company Manufacture pharmaceutical products, bulk drugs and chemicals. It was promoted by Abbott Laboratories, Chicago, U.S.A. which held 100% of the beneficial interest in the subscribed and ...

Piper Sandler initiated coverage on Abbott Laboratories (NYSE:ABT) with an "overweight" rating and a price target of $131 per ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...